Roche's Gazyva to steal rituximab's CLL crown
This article was originally published in Scrip
Executive Summary
Roche/Genentech's Gazyva (obinutuzumab) has overthrown Rituxan (rituximab) as a first-line treatment for chronic lymphocytic leukemia (CLL) according to full Phase III study results presented at the American Society for Hematology (ASH) annual conference in New Orleans.